Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 5, 2008, Pages 648-654

  Schroecksnadel, Katharina ^a   Walter, Roland B ^b   Weiss, Guenter ^a   Mark, Michael ^c   Reinhart, Walter H ^c   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Fred Hutchinson Cancer Research Center   (United States)

^c KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Coronary heart disease; Cysteine; Gender difference; Homocysteine; Neopterin

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYSTEINE; HOMOCYSTEINE; NEOPTERIN; THIOL DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DISEASE MARKER; FEMALE; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CYSTEINE; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; PREDICTIVE VALUE OF TESTS; SULFHYDRYL COMPOUNDS;

EID: 44349086524     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.121     Document Type: Article

References (33)

1. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Basha BJ, Sowers JR. Atherosclerosis: an update. Am Heart J 1996;131:1192-202.
4. Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997;30:703-7.
5. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19:2355-63.
6. Auer J, Berent R, Labetanig E, Eber B. Serum neopterin and activity of coronary artery disease. Heart Dis 2001;3:297-301.
7. Ozkan Y, Ozkan E, Simsek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002;82:269-77.
8. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39:632-7.
9. Zylberstein DE, Bengtsson C, Bjorkelund C, Landaas S, Sundh V, Thelle D, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004;109:601-6.
10. Taniguchi H, Momiyama Y, Ohmori R, Yonemura A, Yamashita T, Tamai S, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease. Atherosclerosis 2005;178:173-7.
11. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528-36.
12. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992;29:307-41.
13. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991;89:203-8.
14. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994;106:263-71.
15. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000;35:956-62.
16. van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW, et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003;92:1201-3.
17. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, et al. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol 2004;93:627-9.
18. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110:1747-53.
19. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005;26:457-63.
20. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007;115:3071-8.
21. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
22. van den Brandhof WE, Haks K, Schouten EG, Verhoef P. The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001;157:403-9.
23. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
24. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
25. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004;5:107-18.
26. Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH. HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. Clin Chem Lab Med 2003;41:1314-9.
27. Frick B, Rudzite V, Schröcksnadel K, Kalnins U, Erglis A, Trusinskis K, et al. Homocysteine, B vitamins and immune activation in coronary heart disease. Pteridines 2003;14:82-7.
28. Faintuch J, Aguilar PB, Nadalin W. Relevance of N-acetylcysteine in clinical practice: fact, myth or consequence? Nutrition 1999;15:177-9.
29. Frick B, Rudzite V, Schröcksnadel K, Kalnins U, Erglis A, Trusinskis K, et al. Homocysteine, B vitamins and immune activation in coronary heart disease. Pteridines 2003;14:82-7.
30. Schroecksnadel K, Frick B, Kaser S, Wirleitner B, Ledochowski M, Mur E, et al. Moderate hyperhomocysteinae mia and immune activation in patients with rheumatoid arthritis. Clin Chim Acta 2003;338:157-64.
31. Schroecksnadel K, Leblhuber F, Frick B, Wirleitner B, Fuchs D. Association of hyperhomocysteinemia in Alzheimer disease with elevated neopterin levels. Alzheimer Dis Assoc Disord 2004;18:129-33.
32. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003;134:53-6.
33. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.